Report cover image

U.S. Oncology Based Molecular Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Technology, By Type – Market Forecast, 2025–2034

Publisher Polaris Market Research & Consulting LLP
Published Oct 01, 2025
SKU # PLRS20566082

Description

The U.S. oncology based molecular diagnostics market size is expected to reach USD 2.29 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Oncology Based Molecular Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Technology, By Type – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The field of oncology-based molecular diagnostics focuses on analyzing the genetic and molecular makeup of a cancer patient. It involves various tests that study DNA, RNA, and proteins to find specific genetic mutations, gene expressions, and other biomarkers linked to a tumor. This information helps doctors better understand the disease, choose the most effective and targeted therapies, and monitor patient’s response to the treatment. These tests are a key part of the move toward personalized medicine, as they enable a deeper, more tailored approach to cancer care.

The U.S. oncology based molecular diagnostics market is experiencing strong growth due to the rising number of cancer cases and the increasing adoption of precision medicine. The market growth is also being fueled by ongoing technological advancements, particularly in areas such as next-generation sequencing and liquid biopsy, which make diagnostics faster and less invasive. There is also a greater focus on government and private investments in cancer research, which is leading to the development of new diagnostic tools. Overall, the market is expanding as these technologies become more integrated into routine clinical practice, helping to improve cancer diagnosis and patient outcomes.

U.S. Oncology Based Molecular Diagnostics Market Report Highlights:

By product, the reagents segment held the largest share in the market in 2024 due to its nature as a consumable product. They are essential for performing diagnostic tests, which creates a constant and recurring demand that is directly tied to the overall volume of testing.

By technology, the polymerase chain reaction (PCR) segment held the largest share in 2024. Its widespread use is a result of it being a well-established, reliable, and cost-effective method that is commonly used in clinical labs for various diagnostic procedures.

By type, the breast cancer segment held the largest share in 2024 due to the high number of breast cancer cases and a strong emphasis on early detection and screening. Molecular diagnostics play a critical role in treatment planning for this type of cancer by helping to identify key biomarkers.

A few key players in the market include Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Illumina, Abbott, Agilent Technologies, Danaher, Hologic, Myriad Genetics, and Sysmex.

Polaris Market Research has segmented the U.S. oncology based molecular diagnostics market report based on product, technology, and type:

By Product Outlook (Revenue – USD Billion, 2020–2034)

Instruments

Reagents

Others

By Technology Outlook (Revenue – USD Billion, 2020–2034)

PCR

In situ hybridization

INAAT

Sequencing

Others

By Type Outlook (Revenue – USD Billion, 2020–2034)

Breast Cancer

Prostate Cancer

Colorectal Cancer

Cervical Cancer

Liver Cancer

Lung Cancer

Blood Cancer

Kidney Cancer

Others

Table of Contents

1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Source
3.2.1. Primary Source
3.2.2. Secondary Source
4. U.S. Oncology Based Molecular Diagnostics Market Insights
4.1. U.S. Oncology Based Molecular Diagnostics Market – Market Snapshot
4.2. U.S. Oncology Based Molecular Diagnostics Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising Cancer Incidence Rates
4.2.1.2. Increasing Adoption of Personalized Medicine
4.2.2. Restraints and Challenges
4.2.2.1. Regulatory complexities and lengthy approval processes
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Oncology Based Molecular Diagnostics Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. U.S. Oncology Based Molecular Diagnostics Market, by Product
5.1. Key Findings
5.2. Introduction
5.2.1. U.S. Oncology Based Molecular Diagnostics Market, by Product, 2020–2034 (USD Billion)
5.3. Instruments
5.3.1. U.S. Oncology Based Molecular Diagnostics Market, by Instruments, by Region, 2020–2034 (USD Billion)
5.4. Reagents
5.4.1. U.S. Oncology Based Molecular Diagnostics Market, by Reagents, by Region, 2020–2034 (USD Billion)
5.5. Others
5.5.1. U.S. Oncology Based Molecular Diagnostics Market, by Others, by Region, 2020–2034 (USD Billion)
6. U.S. Oncology Based Molecular Diagnostics Market, by Technology
6.1. Key Findings
6.2. Introduction
6.2.1. U.S. Oncology Based Molecular Diagnostics Market, by Technology, 2020–2034 (USD Billion)
6.3. PCR
6.3.1. U.S. Oncology Based Molecular Diagnostics Market, by PCR, by Region, 2020–2034 (USD Billion)
6.4. In situ hybridization
6.4.1. U.S. Oncology Based Molecular Diagnostics Market, by In situ hybridization, by Region, 2020–2034 (USD Billion)
6.5. INAAT
6.5.1. U.S. Oncology Based Molecular Diagnostics Market, by INAAT, by Region, 2020–2034 (USD Billion)
6.6. Sequencing
6.6.1. U.S. Oncology Based Molecular Diagnostics Market, by Sequencing, by Region, 2020–2034 (USD Billion)
6.7. Others
6.7.1. U.S. Oncology Based Molecular Diagnostics Market, by Others, by Region, 2020–2034 (USD Billion)
7. U.S. Oncology Based Molecular Diagnostics Market, by Type
7.1. Key Findings
7.2. Introduction
7.2.1. U.S. Oncology Based Molecular Diagnostics Market, by Type, 2020–2034 (USD Billion)
7.3. Breast Cancer
7.3.1. U.S. Oncology Based Molecular Diagnostics Market, by Breast Cancer, by Region, 2020–2034 (USD Billion)
7.4. Prostate Cancer
7.4.1. U.S. Oncology Based Molecular Diagnostics Market, by Prostate Cancer, by Region, 2020–2034 (USD Billion)
7.5. Colorectal Cancer
7.5.1. U.S. Oncology Based Molecular Diagnostics Market, by Colorectal Cancer, by Region, 2020–2034 (USD Billion)
7.6. Cervical Cancer
7.6.1. U.S. Oncology Based Molecular Diagnostics Market, by Cervical Cancer, by Region, 2020–2034 (USD Billion)
7.7. Liver Cancer
7.7.1. U.S. Oncology Based Molecular Diagnostics Market, by Liver Cancer, by Region, 2020–2034 (USD Billion)
7.8. Lung Cancer
7.8.1. U.S. Oncology Based Molecular Diagnostics Market, by Lung Cancer, by Region, 2020–2034 (USD Billion)
7.9. Blood Cancer
7.9.1. U.S. Oncology Based Molecular Diagnostics Market, by Blood Cancer, by Region, 2020–2034 (USD Billion)
7.10. Kidney Cancer
7.10.1. U.S. Oncology Based Molecular Diagnostics Market, by Kidney Cancer, by Region, 2020–2034 (USD Billion)
7.11. Others
7.11.1. U.S. Oncology Based Molecular Diagnostics Market, by Others, by Region, 2020–2034 (USD Billion)
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. Abbott
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Danaher
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. Hologic
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Illumina
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Myriad Genetics
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. QIAGEN
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Roche Diagnostics
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. Sysmex
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. Thermo Fisher Scientific
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us